Acadia says data from Parkinson's trial enough to file for approval(Reuters) - Acadia Pharmaceuticals Inc said data from an initial late-stage trial would be sufficient to file for approval for its experimental antipsychotic drug for Parkinson's disease patients, and that it would not need to conduct an additional trial as planned earlier. Shares of the company jumped 47 percent to $11.74 in early trade on Thursday. The stock was the biggest percentage gainer on the Nasdaq and more than four million shares had changed hands within the first 10 minutes of trading. The U.S. ...
Source: Acadia says data from Parkinson's trial enough to file for approval (http://news.yahoo.com/acadia-says-data-parkinsons-trial-enough-file-approval-134330141--finance.html)